Takeda Pharmaceutical Co ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
24.8%projected annual EPS growth
Analyst Coverage
3analysts covering
FY Revenue (est.)
$31.2Bnext fiscal year
FY EPS (est.)
$0.34next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| FY2026 Quarter 2 Earnings Announcement | 29 Oct 2026 |
Monitoring Framework
Key Performance Indicators
Core Operating Profit (JPY) Annually1.2TTarget: Stable core operating profit above 1 trillion JPY
Annual Dividend per Share (JPY) Annually200.0Target: Progressive dividend policy with steady increases
Adjusted Free Cash Flow (JPY) Annually684.5BTarget: Sustain strong cash balance to fund R&D and deleverage
Watch Items
- Zasocitinib (TAK-279) Phase 3 Psoriasis Data & Immunology ExpansionTrigger: Regulatory submissions and approvals in major global marketsAction: Monitor clinical trial updates, FDA/EMA filing timelines, and competitive positioning against other TYK2/JAK inhibitors.
- AMITIZA Antitrust Litigation Verdict & AppealTrigger: Final court ruling on the appeal processAction: Assess potential cash flow constraints, impact on capital allocation priorities, and dividend coverage safety.
- CEO Transition to Julie KimTrigger: Execution of strategic pipeline launches and organizational restructuringAction: Evaluate management's ability to drive core operating profit margin expansion and integrate new launch products.
Research as of 2 Sep 2026